Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
Looks to enable patients all over the world to have equal access to the highest quality of cancer care and...
Looks to enable patients all over the world to have equal access to the highest quality of cancer care and...
John O'Dwyer photograph International Myeloma Foundation (IMF) welcomes lifelong philanthropist and myeloma survivor John O'Dwyer to the IMF Board of...
STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Introduction This article delves into the most advanced and effective cancer treatment options currently available. It provides an in-depth analysis...
NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology...
Board will help advance the mission and support development of our game-changing IUD for contraception (3D-001)MANSFIELD, Mass., March 13, 2024...
New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers Active...
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to...
NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare...
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next...
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided...
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy...
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2...
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW...
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 --...
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q...
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / We're committed to increasing diverse representation in clinical trials, especially for...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune...